Stroke prevention for patients with atrial fibrillation: Improving but not perfect yet

Heart

Volumn 99, Issue 16, 2013, Pages 1141-1142

  Sandh, Roopinder K ^a   McAlister, Finlay A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EDITORIAL; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORBIDITY; MORTALITY; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ANTICOAGULANTS; ATRIAL FIBRILLATION; GENERAL PRACTICE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; STROKE;

EID: 84880594975     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-303656     Document Type: Editorial

References (17)

1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25.
2. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158:229-34.
3. Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart 2013;99:1166-72.
4. Sandhu R, Bakal JA, Ezekowitz JA, et al. The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. Am Heart J 2011;161:986-92.
5. McAlister FA. Atrial fibrillation, shared decision making, and the prevention of stroke. Stroke 2002;33:243-4.
6. Sandhu RK, Bakal JA, Ezekowitz JA, et al. Risk stratification schemes, anticoagulation use and outcomes: The risk - treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart 2011;97:2046-50.
7. Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with af in the uk: an analysis using the general practice research database (GPRD) 2000-2009. Heart 2013;99:127-32.
8. Friberg L, Hammar N, Ringh M, et al. Stroke prophylaxis in atrial fibrillation: Who gets it and who does not? Report from the stockholm cohort-study on atrial fibrillation (SCAF-Study). Eur Heart J 2006;27:1954-64.
9. McAlister FA, Man-Son-Hing M, Straus SE, et al. Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. CMAJ 2005;173:496-501.
10. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78.
11. Rash A, Downes T, Portner R, et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007;36:151-6.
12. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72.
13. Bungard TJ, Ghali WA, McAlister FA, et al. Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ 2001;165:301-2.
14. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96.
15. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503.
16. Van Spall HG, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2012;126:2309-16.
17. Hendriks JM, de Wit R, Crijns HJ, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: Results of a randomized trial of integrated chronic care vs. Routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J 2012;33:2692-9.